# The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2

> **NCT07146230** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Montefiore Medical Center** · enrollment: 52 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Monalizumab
- **DRUG:** Oleclumab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT07146230
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-12
- **Final completion:** 2028-10
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07146230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07146230, "The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07146230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*